For the first time in the US, adults living with familial chylomicronemia syndrome (FCS) have an FDA-approved treatment option. Ionis Pharmaceuticals recently announced that its drug, Tryngolza (olezarsen), has been approved as an adjunct to diet for the reduction of triglyceride levels in FCS patients, who have long faced a condition with no existing pharmacological […]
